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Tumor-associated lymphatic vessels (LVs) play multiple roles during tumor progression, 
including promotion of metastasis and regulation of antitumor immune responses by 
delivering antigen from the tumor bed to draining lymph nodes (LNs). Under steady-state 
conditions, LN resident lymphatic endothelial cells (LECs) have been found to maintain 
peripheral tolerance by directly inhibiting autoreactive T-cells. Similarly, tumor-associated 
lymphatic endothelium has been suggested to reduce antitumor T-cell responses, but 
the mechanisms that mediate this effect have not been clarified. Using two distinct 
experimental tumor models, we found that tumor-associated LVs gain expression of the 
T-cell inhibitory molecule PDL1, similar to LN resident LECs, whereas tumor-associated 
blood vessels downregulate PDL1. The observed lymphatic upregulation of PDL1 was 
likely due to IFN-g released by stromal cells in the tumor microenvironment. Furthermore, 
we found that blocking PDL1 results in increased T-cell stimulation by antigen-presenting 
LECs in  vitro. Taken together, our data suggest that peripheral, tumor-associated 
lymphatic endothelium contributes to T-cell inhibition, by a mechanism similar to 
peripheral tolerance maintenance described for LN resident LECs. These findings may 
have clinical implications for cancer therapy, as lymphatic expression of PDL1 could 
represent a new biomarker to select patients for immunotherapy with PD1 or PDL1 
inhibitors.
Keywords: peripheral tolerance, immune checkpoint, tumor vasculature, lymph node, PD1, abortive proliferation, 
T-cell exhaustion, tumor-induced immunosuppression
inTrODUcTiOn
The lymphatic system comprises lymphatic capillaries and collecting vessels, as well as lymph 
nodes (LNs), and it exerts several essential functions in the body. Lymphatic vessels (LVs) take 
up interstitial fluid in peripheral tissues and transport it back to the blood circulation, thus 
maintaining basic tissue fluid homeostasis. At the same time, the lymphatic system provides a 
route for the recirculation of immune cells, such as memory T-cells, which constantly patrol the 
body, shuttling between the blood circulation and peripheral tissues. Similarly, dendritic cells and 
other antigen-presenting cells (APCs) use LVs to transport antigen taken up in the periphery to 
draining LNs, where they make contact with naive T- and B-lymphocytes to initiate adaptive 
immune responses. Consequently, the lymphatic system is closely connected to the immune system 
and the regulation of immune responses (1).
2Dieterich et al. PDL1 on Tumor-Associated Lymphatic Vessels
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 66
In pathological conditions, such as acute and chronic 
inflammation or cancer, peripheral LVs, and also draining 
LNs, undergo a dramatic expansion which is mediated by the 
enlargement of existing vessels as well as induction of de novo 
LV formation (lymphangiogenesis) (2–4). These effects are 
predominantly mediated by lymphangiogenic growth factors 
such as VEGF-C, produced at the site of inflammation or 
neoplastic growth. VEGF-C acts locally on nearby LVs, but 
may also be transported via the lymph to the draining LNs 
(5). Depending on the type of the inflammatory insult, the 
outcome of this expansion (and the concomitant increase in 
fluid drainage) may have beneficial or negative effects for the 
patient. For example, we and others have found that activation 
of LV expansion by administering VEGF-C decreases acute and 
chronic skin inflammation as well as rheumatoid arthritis (6–8), 
likely due to increased drainage of inflammatory factors and 
activated immune cells away from the site of inflammation. On 
the other hand, in cancer patients, an increased LV density in and 
around the tumor facilitates the lymphogenous spread of tumor 
cells and consequently correlates with LN metastasis and a poor 
prognosis (3, 4). At the same time, deficient lymphatic drainage 
in experimental tumor models reduces tumor inflammation and 
infiltration by immune effector cells, probably due to a lack of 
tumor-derived antigen reaching the local LNs which results in 
a state of “immunologic ignorance” of the tumor (9, 10).
Apart from these drainage-related effects, lymphatic 
endothelial cells (LECs) are also increasingly recognized as 
direct regulators of the immune system. LECs may act as non-
professional APCs, expressing both MHC class I and class II 
molecules, which enable them to directly interact with T-cells 
and to modulate their activation status. This immune-regulatory 
function of LECs is particularly well studied in the case of LN 
resident LECs. Victor Engelhard and coworkers reported that 
LN LECs, but not LECs in peripheral LVs, express various self-
antigens, including the melanocyte-specific antigen tyrosinase. 
Furthermore, LECs present peptides derived from these self-
antigens on MHCI complexes to CD8+ T-cells and inhibit their 
activation in an antigen-dependent manner, thus eliminating 
autoreactive T-cells and maintaining peripheral tissue tolerance 
(11–13). LN LECs have also been found to take up free antigen 
from the lymph and to cross-present it to CD8+ T-cells, which 
may result in blunted T-cell responses to exogenous antigens 
(14). Taken together, the current data point to LN LECs being 
broadly inhibitory for CD8+ T-cells, both toward endogenous 
and exogenous antigens, at least under steady-state conditions. 
Whether LN LECs similarly interact with and inhibit CD4+ 
T-cells has remained somewhat controversial. On the one 
hand, LN LECs do express MHCII, but their ability to load it 
with antigen-derived peptides appears to be impaired due to a 
lack of H2-M expression (15). On the other hand, transfer of 
peptide-loaded MHCII complexes and/or antigen between LN 
LECs and other APCs, such as dendritic cells, has been reported, 
indicating that LN LECs may indeed play a role in the regulation 
of CD4+ T-cell responses (15, 16).
Various mechanisms how LN LECs control T-cells have been 
suggested, including a relative lack of co-stimulatory molecules 
and inhibition of T-cells via interaction of MHCII with LAG3 on 
the T-cell surface (11, 12, 15). In addition, LN LECs have been 
found to constitutively express the immune checkpoint molecule 
PDL1 (also called CD274 or B7H1), which inhibits T-cells via 
activation of the PD1 receptor, typically inducing a state of T-cell 
unresponsiveness termed “T-cell exhaustion” (17). However, in 
the case of peripheral tolerance induced by LN LECs in vivo, the 
effect on transferred autoreactive T-cells was reported to differ 
substantially from classical exhaustion, as those T-cells initially 
proliferated but subsequently became eliminated from the 
recipient mice (12), a process which has been termed “abortive 
proliferation.” In any case, the precise role of PDL1 expression in 
this process has not been entirely elucidated.
Steady-state PDL1 expression in LN LECs has been reported 
to be dependent on lymphotoxin signaling in the LN microen-
vironment (11). Additionally, PDL1 expression is inducible in 
various cell types, such as myeloid cells and endothelial cells 
(ECs), by inflammatory cytokines, particularly by IFN-g (18, 
19). Therefore, PDL1 acts as a negative feedback regulator of 
Th1/CD8+ T-cell immune responses, which are characterized by 
high IFN-g release. Correspondingly, acute skin inflammation 
induced by repeated application of the contact sensitizer oxa-
zolone, which triggers a Th1-biased immune response, resulted 
in a strong upregulation of PDL1 mRNA in isolated LECs (20). 
Similarly, PDL1 was upregulated in LECs upon antigen-specific 
interaction with CD8+ T-cells in vitro (14).
With regards to cancer, the role of LECs in regulating 
T-cell immunity is incompletely understood. Overexpression 
of VEGF-C in the B16F10 mouse melanoma model has been 
reported to decrease endogenous CD8+ T-cell responses against 
a model antigen (ovalbumin) and to turn these tumors refractory 
to adoptive T-cell transfer with OT-1 T-cells. Furthermore, these 
authors observed presentation of tumor antigen by peripheral 
and LN LECs, suggesting that LECs may contribute directly to 
the inhibition of T-cell-mediated antitumor immune responses 
(21). However, the mechanisms behind the T-cell inhibition by 
tumor-associated LECs have not been investigated so far.
We hypothesized that tumor-associated LECs might upregu-
late PDL1 in response to tumor-derived signals, and might thus 
contribute to the inhibition of tumor specific T-cells. Using two 
distinct syngeneic tumor models in different mouse strains, 
namely intradermal injection of VEGF-C overexpressing B16F10 
melanomas and an orthotopic breast cancer model (4T1), we 
found that PDL1 is significantly upregulated in peripheral, 
tumor-associated LVs, presumably in response to IFN-g secreted 
by cells present in the tumor stroma. Using ovalbumin as model 
antigen, we provide direct evidence that PDL1 indeed reduces the 
stimulation of CD8+ T-cells by antigen-presenting LECs.
resUlTs
PDl1 is Upregulated in  
Tumor-associated lVs
Previously, LVs in B16F10 melanomas overexpressing VEGF-C 
were reported to inhibit specific T-cell immunity (21), but 
the molecular mechanisms behind this inhibition have 
remained unclear. To investigate whether PDL1 is expressed in 
FigUre 1 | PDl1 is expressed in tumor-associated lymphatic vessels (lVs). (a) Representative images of LVs (stained for LYVE-1, red) in control (Ctr) back 
skin (C57BL/6 background, top row) and B16F10-VEGFC melanoma (bottom row) co-stained for PDL1 (green). (B) Quantification of PDL1 staining intensity within 
the LYVE-1+ area of LVs in control back skin (N = 98 vessels from 10 individual mice), in the inner tumor mass of B16F10-VEGFC tumors (N = 17 vessels from six 
individual mice) and in the tumor periphery (N = 34 vessels from seven individual mice). (c) Similar to the B16F10-VEGFC model, PDL1 staining in LYVE-1-positive 
LVs was absent in the abdominal skin of BALB/c mice (top row) but was observed in 4T1 breast cancer-associated LVs (bottom row). (D) Quantification of PDL1 
staining intensity within the LYVE-1+ area of LVs in control abdominal skin (N = 42 vessels from five individual mice), in the inner tumor mass of 4T1 tumors (N = 40 
vessels from six individual mice), and in the tumor periphery (N = 35 vessels from five individual mice).
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tumor-associated LVs, we implanted VEGF-C overexpressing 
B16F10 melanoma cells [B16F10-VEGFC (22)] intradermally into 
syngeneic C57BL/6 mice, and analyzed the expression of PDL1 
by immunofluorescence staining of tumor sections 2 weeks later. 
Using LYVE-1 staining to identify LVs within the tumor mass and 
in the tumor periphery, we found increased PDL1 staining within 
the lymphatic endothelium of tumor-associated LVs, compared 
to LVs in the back skin of naive C57BL/6 mice (Figure 1A). In 
addition, diffuse PDL1 staining in a subset of tumor cells and in 
single, tumor-infiltrating cells could be observed. Image-based 
quantification of the PDL1 staining intensity in LYVE-1+ LVs 
confirmed a significant upregulation of the protein in intratu-
moral LVs but not in peritumoral LVs (Figure 1B).
To test whether lymphatic PDL1 expression is dependent on 
the tumor type, high expression of VEGF-C, or on the back-
ground mouse strain used, we next investigated PDL1 expression 
in a second, unrelated tumor model. 4T1 mammary carcinoma 
cells were implanted orthotopically in syngeneic hosts (Balb/c), 
and immunofluorescence stainings for PDL1 were performed 
3 weeks later. Similar to what we found in melanomas, intratu-
moral LVs in 4T1 tumors also expressed PDL1, whereas PDL1 was 
not expressed by peritumoral LVs and LVs of the abdominal skin 
and the mammary fat pad of naive Balb/c mice (Figures 1C,D).
As PDL1 might be expressed by various cell types, including 
immune cells which sometimes reside in very close proximity 
to LVs and may thus confound the microscopic analysis, we 
next performed FACS analyses of primary B16F10-VEGFC and 
4T1 tumors compared to the corresponding control tissues. 
Antibodies against CD45, CD31, and podoplanin (PDPN) were 
used to differentiate between immune cells, blood vascular 
endothelial cells (BECs), and LECs (Figure 2A). Analysis of the 
fluorescence intensity confirmed that in both tumor models, 
FigUre 2 | PDl1 is upregulated in tumor-associated lymphatic vessels but down-regulated in tumor-associated blood vessels. (a) Example FACS plots 
to illustrate the gating strategy used to identify lymphatic endothelial cells (LECs) and blood vascular endothelial cells (BECs) in skin samples and tumors. Left panel: 
total endothelial cells (ECs) were identified as CD31+CD45− cells in a control skin sample (pre-gated for living singlets). Right panel: LECs were differentiated from 
BECs by staining for podoplanin (PDPN). (B) Example histogram of PDL1 staining intensity measured by FACS in LECs of control (Ctr) back skin and B16F10-VEGFC 
tumors. (c) Quantification of staining intensity in control (Ctr) back skin and B16F10-VEGFC-associated LECs (N = 5 mice/group). (D) Example histogram of PDL1 
staining intensity measured by FACS in LECs of control abdominal skin and 4T1 tumors. (e) Quantification of staining intensity in control abdominal skin and 
4T1-associated LECs (N = 4 mice/group; one out of two experiments with similar results is shown). (F,g) Quantification of PDL1 staining intensity in BECs of 
B16F10-VEGFC tumors [(F), N = 5 mice/group) and of 4T1 tumors [(g), N = 4 mice/group; one out of two experiments with similar results is shown].
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tumor-associated LECs expressed higher levels of PDL1 than 
LECs in normal skin (Figures 2B–E). It is of interest that PDL1 
expression on BECs showed the opposite behavior, with a sig-
nificant reduction in PDL1 expression in tumor-associated BECs 
compared to normal skin BECs (Figures 2F,G), indicating that 
BECs react very differently to stimuli derived from the tumor 
microenvironment. To investigate whether PDL1 expression by 
LVs might be induced only in very late stages of tumor growth, 
and might thus not be relevant for the inhibition of T-cell 
responses, which are likely triggered during the early growth 
phase of tumors, we next analyzed lymphatic PDL1 expression 
already 8 days after 4T1 implantation. Similar to our observation 
at the 3-week time point, we found PDL1 induced in LECs and 
reduced in BECs (Figure S1 in Supplementary Material).
PDl1 expression in ln stromal cells is 
not affected by the Presence of an 
Upstream Tumor
Lymph node LECs have previously been reported to express 
PDL1 under steady-state conditions, depending on lympho-
toxin signaling (11). Cytokines and growth factors drained from 
an upstream inflammatory site or a tumor mediate expansion of 
the lymphatic vasculature of the draining LN [reviewed in Ref. 
(2)], but their effect on the PDL1 expression by LN LECs has not 
been investigated. We therefore analyzed the PDL1 expression 
in the major LN stromal cell subsets [CD31+/podoplanin+ 
LECs, CD31+/podoplanin− BECs, CD31−/podoplanin+ fol-
licular reticular cells (FRCs), and CD31−/podoplanin− double 
negative (DN) cells; Figure 3A] in tumor draining inguinal LNs 
and in inguinal LNs of naive mice. In agreement with previous 
reports (12), we found that LECs expressed the highest PDL1 
levels among those cell types. The surface levels of PDL1 did not 
change significantly in response to the presence of an upstream 
tumor (Figure 3B). BECs also expressed considerable amounts 
of PDL1 on their cell surface. In line with our observations in 
primary tumors, PDL1 expression on LN BECs was reduced in 
tumor bearing mice, especially in the 4T1 breast cancer model 
(Figure 3C). PDL1 expression in FRCs and in DN cells was gen-
erally very low and was only slightly increased by the presence of 
an upstream tumor (Figures 3D,E). Taken together, these data 
indicate that LN LEC expression of PDL1 is constitutively high 
and is not affected by cytokines or other factors drained from 
upstream tumors.
PDl1 expression in lecs is regulated 
by iFn-g
To elucidate how PDL1 expression is regulated in tumor- 
associated LECs, we treated immortalized mouse LECs 
(imLECs) with several (lymph-) angiogenic growth factors 
(VEGF-A, VEGF-C) and inflammatory cytokines (IFN-g, 
TNF-a), all of which are commonly expressed in the microen-
vironment of various tumors. Using qPCR, we found a strong 
upregulation of PDL1 mRNA expression in imLECs treated 
with IFN-g (up to 40-fold after 24  h). TNF-a had only very 
minor effects on PDL1 expression (up to twofold induction), 
whereas VEGF-A and VEGF-C had no effect at all (Figure 4A). 
IFN-g mediated induction of PDL1 expression was also 
reflected at the protein level: using FACS analysis, we found 
that imLECs constitutively express PDL1 on their surface and 
dramatically upregulated it upon treatment with IFN-g for 24 h 
(Figures 4B,C). To test whether tumor cells can directly induce 
PDL1 expression in LECs via secretion of one or several solu-
ble factors (e.g., IFN-g), we treated imLECs with conditioned 
media from B16F10-VEGFC and 4T1 cells. Using qPCR and 
FACS, we only detected a minor induction of PDL1 by tumor 
cell conditioned media (Figures 4D–F). In line with this, IFN-g 
expression was not detectable in cultured B16F10-VEGFC cells 
and in 4T1 cells (data not shown), whereas IFN-g expression 
in total tumor tissue was readily detectable and was increased 
compared to the skin of corresponding naive mice in both 
tumor models (Figures 4G,H). Taken together, these findings 
suggest that cells present in the tumor stroma, for example infil-
trating immune cells, are responsible for the induction of PDL1 
expression in tumor-associated LVs via secretion of IFN-g.
T-cells Physically interact with Tumor-
associated lVs In Vivo
Previously, it has been reported that in VEGF-C overexpressing 
B16F10 melanomas, adoptively transferred T-cells were often 
clustering around tumor-associated LVs, indicating a physical 
interaction between T-cells and LECs (21). Using double immu-
nofluorescence stainings for the lymphatic marker LYVE-1 and 
for CD4 or CD8 to identify helper T-cells and cytotoxic T-cells 
in B16F10-VEGFC tumors, we found that endogenous T-cells, 
although relatively few in number, occasionally interacted with 
LECs, both at the luminal and the abluminal side of the endothe-
lium (Figure  5A). Very similar results were obtained when 
we analyzed 4T1 breast cancer tissue (Figure  5B). Given that 
tumor-associated LVs express elevated levels of PDL1, this find-
ing suggests that tumor-infiltrating T-cells may receive inhibitory 
signals from LECs either while still residing in the tumor stroma, 
or upon exiting it via the lymphatic system in route toward the 
draining LNs.
PDl1 inhibits antigen-Dependent 
activation of T-cells by lecs
Previously, it has been reported that presentation of the 
ovalbumin-derived, MHCI-restricted peptide SIINFEKL by 
cultured imLECs to OT-1 CD8+ T-cells reduces their activation 
as compared to peptide-presenting dendritic cells, with a blunted 
upregulation of CD25 and reduced expression of IFN-g by OT-1 
cells (14). Whereas upregulation of PDL1 by peptide-presenting 
imLECs was observed, its role in imLEC–OT-1 interaction was 
not investigated (14). We hypothesized that PDL1 expressed 
(and upregulated) by antigen-presenting imLECs might at least 
in part be responsible for the reduced OT-1 stimulation. Using 
the same in  vitro model system, we confirmed that imLECs 
upregulate surface PDL1 upon SIINFEKL peptide presentation 
to OT-1 T-cells, whereas PDL1 was not upregulated in absence 
of a specific antigen (Figure 6A). Next, we used a PDL1-blocking 
antibody to determine the role of PDL1 during imLEC-mediated 
OT-1 activation. FACS analyses revealed that blockade of PDL1 
FigUre 3 | PDl1 is constitutively expressed in lymph node (ln) lymphatic endothelial cells (lecs) and is not affected by the presence of an 
upstream tumor. (a) Example FACS plots of a LN (pre-gated for living singlets). CD45− LN stromal cells (left, LNSC) were separated into podoplanin (PDPN)+/
CD31− follicular reticular cells (FRCs), PDPN+/CD31+ LECs, PDPN−/CD31+ BECs, and PDPN−/CD31− “double negative” (DN) cells (right panel). (B–e) 
Quantification of PDL1 staining intensity by FACS in LN LECs (B), BECs (c), FRCs (D), and DNs (e) in B16F10-VEGFC draining inguinal LNs (left panels, N = 5 
mice/group) and 4T1 draining inguinal LNs (right panels, N = 4 mice/group; one out of two experiments with similar results is shown), compared to control (Ctr) LNs 
in naive mice. LECs expressed the highest levels of PDL1. Only minor changes in PDL1 expression levels of BECs and FRCs in 4T1 draining LNs were observed.
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FigUre 4 | lymphatic endothelial cells (lecs) upregulate PDl1 in response to iFn-g. (a) Immortalized mouse LECs (imLECs) were treated with VEGF-A 
(20 ng/ml), VEGF-C (200 ng/ml), TNF-a (40 ng/ml), or IFN-g (100 ng/ml). Expression of PDL1 was assessed by qPCR after 6, 24, and 48 h. Incubation with IFN-g 
resulted in a significant upregulation of PDL1 mRNA (pooled data of three individual experiments are shown). (B) Example histogram of surface PDL1 expression 
assessed by FACS in imLECs treated with TNF-a or IFN-g or not (Ctr). (c) Quantification of surface PDL1 in untreated (Ctr), TNF-a treated, and IFN-g treated 
imLECs (N = 3). (D) qPCR showing PDL1 expression upon imLEC treatment with tumor cell conditioned media (Cond med) derived from B16F10-VEGFC or 4T1 
cells, compared to control media (Ctr med) (pooled data of three individual experiments are shown). (e) Example histograms of surface PDL1 expression assessed 
by FACS in imLECs treated with B16F10-VEGFC (left) or 4T1 cell conditioned medium (right). (F) Quantification of surface PDL1 expression in imLECs treated with 
control (Ctr med) or tumor cell conditioned media (Cond med) (N = 3). (g,h) qPCR data showing IFN-g expression in B16F10-VEGFC (g) and 4T1 tumor tissue 
(h) compared to control tissue (back skin resp. abdominal skin) (N = 7–9 for B16F10-VEGFC and 4–7 for 4T1).
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increased the expression of CD25 and IFN-g in OT-1 cells upon 
coculture with SIINFEKL-presenting imLECs (Figures  6B–D). 
Increased activation of OT-1 cells after PDL1 blockade also 
resulted in an elevated capacity to kill ovalbumin-expressing 
B16F10 tumor cells in  vitro (Figure S2A in Supplementary 
Material). Interestingly, we also observed a strong upregulation 
of PDL1 by antigen-stimulated OT-1 T-cells themselves (Figure 
S2B in Supplementary Material), likely due to a paracrine effect of 
FigUre 5 | T-cells interact with tumor-associated lymphatic vessels. Representative images of CD8+ and CD4+ T-cells (green) interacting with LYVE-1+ 
lymphatic endothelial cells (red) in B16F10-VEGFC melanoma (a) and 4T1 breast cancer (B). T-cells interacting with the abluminal (arrows) and the luminal 
(arrowheads) surface of the lymphatic endothelium were observed in both tumor models.
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T-cell secreted IFN-g. Thus, it is possible that the increased acti-
vation of OT-1 T-cells by antigen-presenting imLECs after PDL1 
blockade is partly due to inhibition of OT-1 expressed PDL1, in 
addition to imLEC expressed PDL1. Therefore, we performed 
additional experiments in which PDL1 was specifically blocked 
on the surface of imLECs before coculture with OT-1 cells. Also 
in this setting, we found a potentiating effect of PDL1 blockade on 
OT-1 stimulation, resulting in elevated CD25 expression (Figure 
S2C in Supplementary Material), strongly suggesting that LEC 
expressed PDL1 indeed contributes to LEC-mediated T-cell 
inhibition.
DiscUssiOn
Adaptive immune responses require the cooperation between cells 
of the immune system and the lymphatic vasculature. LNs are the 
principal site where naive T- and B-lymphocytes encounter anti-
gen and where the decision is taken whether these lymphocytes 
become primed to proliferate and develop into effector cells, or 
whether they enter anergy, or even become eliminated (periph-
eral tolerance). Foreign and self-antigens are transported to the 
LNs via the lymphatic system, either as “cargo” transported by 
professional APCs, or as free molecules or complexes carried with 
FigUre 6 | PDl1 blockade increases antigen-specific stimulation of cD8+ T-cells by lymphatic endothelial cells (lecs). (a) PDL1 surface expression 
on immortalized mouse LECs (imLECs) cocultured with OT-1 CD8+ T-cells and pulsed with SIINFEKL peptide or not (Control) was determined by FACS (N = 3). 
(B) Representative FACS plots of CD25 and IFN-g expression by OT-1 CD8+ T-cells (pre-gated for living singlets) after coculture with control or SIINFEKL-pulsed 
imLECs, in the presence of PDL1-blocking antibodies or control IgG. (c,D) Quantification of CD25+ OT-1 cells (c) and IFN-g+ OT-1 cells (D) by FACS gated as in 
panel (B) (N = 3).
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the lymph flow. Once arrived at the LN, antigens are transferred 
into the T- and B-cell zones, either by the LN conduit system, or 
by LN resident or migratory APCs.
With regards to tumor immunology, some priming of 
naive T-cells has been reported to occur within the tumor 
microenvironment [reviewed in Ref. (23)]; yet, draining LNs 
are still the primary site for the mounting of adaptive immune 
responses. Consequently, using transgenic mice, a lack of or 
disturbed lymphatic draining from the tumor site resulted in 
reduced immune activation, immune cell infiltration into the 
tumor, and cytokine release (9, 10), indicating that antigen 
transport by LVs is required for efficient antitumor immune 
responses. On the other hand, induction of lymphangiogenesis 
by forced expression of VEGF-C resulted in a blunted T-cell 
response in the B16F10 melanoma model (21), suggesting that 
the lymphatic endothelium, within the tumor and/or the drain-
ing LNs, has a direct, T-cell inhibitory function. Interestingly, 
tumor-associated LECs have been reported to present tumor-
derived antigen (ovalbumin) on MHCI (21). Using the same 
tumor model (VEGF-C expressing B16F10 melanoma), we 
demonstrate here that tumor-associated LECs upregulate the 
T-cell inhibitory immune checkpoint molecule PDL1. Our 
data also show that this is neither dependent on the tumor 
model (B16F10) nor on the genetic background (C57BL6) or 
the experimental overexpression of VEGF-C, as PDL1 was also 
upregulated in a completely unrelated tumor model, the 4T1 
breast cancer model in the Balb/c background.
Presentation of antigen on MHCI in combination with PDL1 
expression has been found to be a specific feature of LN LECs 
(11, 12). This phenomenon has been linked to the maintenance 
of peripheral immune tolerance, as LN LECs express and present 
various self-antigens, at least under steady-state conditions, remi-
niscent of the thymic epithelium which is responsible for central 
tolerance (13). The fact that PDL1 is upregulated on tumor-
associated LECs as found here, as well as in acutely inflamed LECs 
(20), suggests that under pathological conditions, a very similar 
T-cell inhibitory mechanism is activated in peripheral LVs as well. 
Of note, we and others have shown that induction of lymphangi-
ogenesis in inflammatory conditions ameliorates inflammation 
and promotes resolution (6–8). It is tempting to speculate that 
direct inhibition of T-cells, in addition to increased lymph drain-
age, may contribute to this effect. In the tumor context, multiple 
pathways and factors have been identified that inhibit the activity 
of tumor-infiltrating lymphocytes, resulting in T-cell anergy or 
exhaustion. Peripheral LECs presenting tumor-derived antigens 
with concomitant PDL1 upregulation by tumor-associated LECs 
may to some extent contribute to overall T-cell inhibition in the 
tumor microenvironment, which is consistent with the observa-
tions made before (21). On the other hand, it is intriguing that 
PDL1 expression on tumor-associated LVs may particularly 
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affect antigen-experienced T-cells, including memory T-cells, 
which have the capacity to recirculate from the tumor site to the 
circulation via the lymphatic system. Therefore, further studies 
are highly warranted to elucidate whether tumor-associated 
LECs particularly inhibit the development of memory responses. 
Inhibition of recirculating T-cells entering LVs may also have 
a negative impact on the priming of additional naive T-cells in 
downstream LNs.
PDL1 is an IFN-g target gene in microvascular ECs (18), and 
our data reveal that IFN-g treatment induces PDL1 expression in 
cultured LECs as well. As we found IFN-g to be expressed in the 
tumor microenvironment of both tumor models that we studied, 
we suggest that the observed PDL1 upregulation in tumor- 
associated LECs is in fact mediated by IFN-g. Consistently, we 
found no major PDL1 induction by tumor cell conditioned 
media, which did not contain significant amounts of this cytokine. 
Therefore, the regulation of PDL1 in LVs in the periphery differs 
from that in the LNs, where it was reported to be dependent on 
lymphotoxin, a specific activator of non-canonical NF-kB signal-
ing (11). As we found no significant effect of TNF-a on PDL1 
expression, at least in vitro, it is likely that only the non-canonical, 
but not the canonical, NF-kB pathway regulates PDL1 expression 
in LN LECs. In line with this concept, the PDL1 expression in LN 
LECs was not affected by the presence of a tumor and thus, by 
tumor-derived factors drained to the LNs.
Surprisingly, we observed the opposite effect on tumor-associ-
ated blood vessels. In contrast to LECs, we found that peripheral 
BECs in the skin express PDL1 under steady-state conditions, but 
that they downregulate it in presence of a tumor. Possibly, PDL1 
upregulation by IFN-g is blocked in tumor-associated BECs due 
to high expression of VEGF-A and the induction of angiogenesis, 
which may interfere with inflammatory activation of BECs (24, 
25). Functionally, PDL1 expression on BECs has been reported 
to inhibit autoreactive CD8+ T-cells in a myocarditis model (26), 
indicating that reduced PDL1 expression in tumor-associated 
BECs might facilitate infiltration of activated effector T-cells into 
the tumor stroma. However, further studies are needed to test this 
hypothesis and to investigate whether the PDL1 expression level 
on tumor BECs is higher in tumor models that show no T-cell 
infiltration at all.
Despite the findings that PDL1 is constitutively expressed by 
LN LECs (11, 12) and that it is upregulated on tumor-associated 
LECs as identified here, its precise role in LEC-mediated T-cell 
inhibition is not entirely clear. Treating naive mice with PDL1-
blocking antibodies resulted in the development of autoimmune 
vitiligo after transfer of T-cells specific for the melanocyte-
specific antigen tyrosinase (12). Using chimeric mice carrying 
PDL1−/− bone marrow, it was furthermore reported that the 
inhibition of autoreactive T-cells was mediated by a PDL1+, 
radioresistant stromal cell type, consistent with LN LECs 
being responsible for the maintenance of peripheral tolerance 
toward tyrosinase in this model (12). Similarly, cultured LECs 
presenting the ovalbumin-derived SIINFEKL peptide to OT-1 
CD8+ T-cells have been described to upregulate PDL1 and to 
activate OT-1 cells much less effectively than dendritic cells, 
resulting in reduced expression of the activation marker CD25 
and production of IFN-g (14). Nonetheless, no direct evidence 
that PDL1 expression by LECs is indeed required and/or suf-
ficient for T-cell inhibition has been published so far. Using the 
same in vitro system of cultured LECs presenting the SIINFEKL 
peptide to OT-1 cells, we reveal here that inhibition of PDL1 
with a blocking antibody indeed increases CD25 and IFN-g 
expression by OT-1 cells, and harnesses them for killing of 
ovalbumin-expressing tumor cells. As OT-1 cells themselves 
strongly upregulate PDL1 in this setting (indicating that PDL1 
expression might serve as a sensitive marker of T-cell activa-
tion), we also pre-blocked PDL1 specifically on the LEC surface 
before coculturing them with OT-1 cells. This way of PDL1 
blockade is conceivably less efficient than adding the blocking 
antibodies throughout the coculture period, due to additional 
PDL1 upregulation by the imLECs during this time period. 
Furthermore, dynamic antibody binding and dissociation may 
still result in some PDL1 blockade on the OT-1 T-cells during 
the coculture. Nonetheless, our observation that the activation 
of OT-1 cells was increased even in this setting further supports 
the notion that LEC expressed PDL1 at least partially dampens 
the activation of T-cells by antigen-presenting LECs. However, 
based on our data, an additional role of T-cell expressed PDL1 
acting as a negative feedback regulator of T-cell activation cannot 
be entirely excluded at this moment.
Clinically, the PDL1 expression in cancer has lately received 
considerable attention due to the development of highly potent 
PD1-blocking antibodies (nivolumab and pembrolizumab) 
as well as PDL1-blocking antibodies (e.g., atezolizumab and 
durvalumab) which show dramatic improvements of outcome in 
melanoma patients or are in advanced clinical studies, respec-
tively (27). However, only a subset of patients profits from the 
treatment, and the search for predictive biomarkers to reliably 
identify those patients is ongoing. PDL1 expression on cancer 
cells is currently regarded as such a biomarker and has recently 
been approved by the US Food and Drug Administration as a 
companion or complementary diagnostic test for certain specific 
tumor entities. However, there are difficulties and inconsistencies 
in the clinical protocols to determine the rate of PDL1+ cancer 
cells in biopsy material as there is no fully standardized detection 
antibody, definition of cutoffs for the evaluation of the stain-
ings, tissue preparation, and processing protocols available yet. 
Furthermore, it is debatable whether the currently widely used 
detection in cancer cells itself is the optimal predictive marker 
(28). In this regard, it is interesting that a recent study performed 
in patients with multiple different tumor types found that PDL1 
expression in stromal cells, including tumor-infiltrating leuko-
cytes, was superior in predicting patients who would benefit from 
treatment with a new PDL1-blocking antibody currently under 
development (29). Furthermore, there is growing evidence that 
at least for some malignancies, patients treated with anti-PD1 
antibodies have a survival benefit independent of the expres-
sion of its ligand PDL1 on tumor cells (30). Thus, it is likely that 
additional (stromal) cell types are involved in the inhibition of 
antitumor T-cell responses via the PDL1-PD1 axis. In the light 
of our findings presented here, assessment of the vascular PDL1 
expression may yield additional predictive accuracy and may 
further improve the selection of patients to undergo treatment 
with PD1 or PDL1 inhibitors in the future.
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MaTerials anD MeThODs
cell lines
B16F10 cells expressing luciferase and human VEGF-C have been 
generated and described previously (22). Cells were cultured in 
DMEM containing Glutamax, pyruvate, 10% FBS, and penicillin/
streptomycin (all from Gibco/Thermo Fisher). G418 (1.5 mg/ml, 
Roche) was added to the culture medium to ensure stable expres-
sion of the VEGF-C transgene. 4T1 mammary carcinoma cells 
expressing luciferase (Caliper Life Sciences) were maintained in 
DMEM supplemented with l-glutamine, 10% FBS, and penicil-
lin/streptomycin under standard culture conditions (37°C, 5% 
CO2). ImLECs isolated from H-2Kb-tsA58 (Immorto) mice have 
been described previously (20) and were maintained on collagen 
type I (Advanced Biomatrix)/fibronectin (Millipore) coated 
dishes (10  µg/ml each) in Ham’s F12/DMEM supplemented 
with 20% FBS, 56 µg/ml heparin (Sigma), 10 µg/ml EC growth 
supplement (Abd Serotec/BioRad), penicillin/streptomycin, and 
1 U/ml recombinant mouse IFN-g (Peprotech) at 33°C, 5% CO2. 
Before experiments, cells were cultured at 37°C without IFN-g for 
at least 72 h, which leads to a reduction of the polyoma T antigen 
in these cells.
Mice and Tumor Models
C57BL/6 and Balb/c wild-type mice were obtained from Janvier. 
OT-1 transgenic mice were kindly provided by Dr. Roman 
Spörri and Dr. Annette Oxenius, ETH Zurich. All mice were 
bred in house under SOPF conditions. For the B16F10-VEGFC 
melanoma model, C57BL/6 mice were depilated on the back 
and 2 × 105 tumor cells suspendend in 20 µl PBS were injected 
intradermally into the flank. For the 4T1 breast cancer model, 
1 ×  105 tumor cells suspended in 50 µl PBS were injected into 
the fourth mammary fat pad of Balb/c mice. The primary tumor 
growth was monitored for 2 weeks (B16F10-VEGFC) or 3 weeks 
(4T1) before tissues were prepared for analysis as described 
below. In case of the 4T1 model, some FACS analyses were already 
performed at day 8 after implantation. All tumor studies were 
performed in agreement with the regulations of the local ethical 
board (Kantonales Veterinäramt Zürich, license 12/15).
immunofluorescence staining and image 
analysis
Tumors were dissected, embedded in OCT compound, snap 
frozen, and stored at −80°C until preparation of cryosections 
(7 µm). For stainings, sections were air-dried, fixed in ice-cold 
acetone and 80% methanol, rehydrated in PBS, and subsequently 
blocked in PBS + 0.2% BSA, 5% donkey serum, 0.3% Triton-X100, 
and 0.05% NaN3 (blocking solution). Primary antibodies [rabbit 
anti-LYVE-1 (1:600, Angiobio), rat anti-PDL1 (2  µg/ml, clone 
10F.9G2, Biolegend), rat anti-CD4 (5 µg/ml, clone H129.19, BD), 
and rat anti-CD8 (5 µg/ml, clone 53.6-7, BD)] suspended in block-
ing solution were incubated at room temperature for 2 h or at 4°C 
over night, followed by extensive washing and incubation with 
Alexa488 or Alexa594-conjugated secondary antibodies (donkey 
anti-rat, donkey anti-rabbit, 10 µg/ml, Life Technologies/Thermo 
Fisher) together with Hoechst33342 (2 µg/ml, Sigma) for nuclear 
counterstaining. Finally, slides were washed extensively again and 
mounted using Mowiol.
Images were taken on a Zeiss Axioskop 2 mot plus with a 10× 
or a 20× objective, or a Zeiss LSM780 inverted confocal micro-
scope at 20×. Image analysis was performed using ImageJ (NIH). 
To determine the staining intensity of PDL1 in LVs, LYVE-1+ 
vessels were selected by thresholding, using size exclusion to 
exclude single LYVE-1+ macrophages. Subsequently, the average 
PDL1 staining intensity within each LV was measured.
Facs analysis of Tumor Tissue and lns
For FACS analysis of tumors and control tissues (back skin and 
abdominal skin, respectively), the tissue was dissected, minced, 
and digested in a collagenase solution [5  mg/ml Collagenase 
II (Sigma), 40 µg/ml DNaseI (Roche)] for 30 min at 37°C. The 
digested tissue was passed through a cell strainer before eryth-
rocyte lysis with PharmLyse (BD). After washing and a second 
filtration step, the cell suspension was labeled with fluorescently 
tagged antibodies [hamster anti-podoplanin-PE (1:400, clone 
8.1.1, eBioscience), rat anti-CD31-APC (1:300, clone MEC13.3, 
BD), rat anti-CD45-APC/Cy7 (1:200, clone 30-F11, Biolegend), 
and rat anti-PDL1-PE/Cy7 (1:200, clone 10F.9G2, Biolegend)]. 
7AAD (Biolegend) was used for life/dead discrimination. Inguinal 
LNs were processed essentially as described before (31). In brief, 
the capsule of dissected LNs was ruptured and the tissue was 
digested with 1 mg/ml Collagenase IV (Gibco)/40 µg/ml DNaseI 
for 20 min at 37°C to release the majority of the immune cells. 
The remaining stromal fragments were washed twice, digested 
with 3.5  mg/ml Collagenase IV/40  µg/ml DNaseI for 15  min 
at 37°C, and disaggregated by pipetting in presence of 0.5 mM 
EDTA. After filtration, the stromal cell enriched cell suspension 
was stained as described above. Data were acquired on a FACS 
CANTO (BD) and analyzed using FlowJo (Treestar Inc.).
lec stimulation In Vitro
imLECs were starved over night in Ham’s F12/DMEM +  1% 
FBS and subsequently stimulated with VEGF-A (20  ng/ml, 
Cell Sciences), VEGF-C (200 ng/ml, R&D), IFN-g (100 ng/ml, 
Peprotech), or TNF-a (40 ng/ml, Peprotech). Tumor cell condi-
tioned media were prepared by culturing 1 × 107 B16F10-VEGFC 
or 4T1 cells in medium supplemented with 1% FBS for 72 h. The 
conditioned media were centrifuged, filtered through a 0.45 µm 
filter, and stored at −80°C until use. ImLECs were stimulated with 
50% conditioned media in Ham’s F12/DMEM + 1% FBS. DMEM 
with Glutamax and pyruvate, or DMEM with l-glutamine (both 
with 1% FBS) served as control media. For FACS analysis, LECs 
were washed with PBS and trypsinized with 0.01% trypsin/
EDTA. Cells were labeled with primary antibody (rat anti-PDL1, 
2 µg/ml, clone 10F.9G2, Biolegend), washed and labeled with a 
secondary antibody (donkey anti-rat-Alexa488, 10  µg/ml, Life 
Technologies/Thermo Fisher). 7AAD was used for life/dead 
discrimination. Data were acquired on a FACS CANTO and 
analyzed using FlowJo.
rna extraction and qPcr
RNA from stimulated LECs was extracted at the indicated 
time points using the Nucleospin RNA kit (Macherey-Nagel) 
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according to the manufacturer’s instructions. Total tumor and 
control tissue RNA was extracted from cryosections using the 
RNeasy Plus Micro kit (Qiagen). All RNA was reverse transcribed 
using the High Capacity cDNA kit (Applied Biosystems/Thermo 
Fisher). qPCR analyses were performed on a 7900HT FAST 
instrument (Applied Biosystems/Thermo Fisher) in triplicate 
using SYBRGreen (Roche). RPLP0 was used as internal reference 
gene. Relative expression (RE) calculated according to the for-
mula REgeneX
Ct CtgeneX RPLP0= − −( )2  and was expressed as fold change 
normalized to the control condition. The primer sequences used 
for qPCR were RPLP0 fwd: AGATTCGGGATATGCTGTTGG, 
rev: TCGGGTCCTAGACCAGTGTTC; PDL1 fwd: ACAAG 
CGAATCACGCTGAAAG, rev: GGCCTGACATATTAGTTCA 
TGCT; and IFNG fwd: ACACTGCATCTTGGCTTTGC, rev: 
CTGGCTCTGCAGGATTTTCA.
OT-1 T-cell activation and Tumor cell 
Killing assay
For OT-1 stimulation experiments, CD8+ OT-1 T-cells were 
isolated from the spleens of naive OT-1 mice using CD8+ MACS 
beads (Miltenyi) according to the manufacturer’s instructions. 
ImLECs were starved over night in Ham’s F12/DMEM + 1% FBS, 
pulsed with 1  ng/ml SIINFEKL peptide (AnaSpec) for 1  h, and 
washed three times with PBS. Subsequently, OT-1 and peptide-
pulsed imLECs were cocultured for 24  h at a 10:1 ratio in the 
presence of 10  µg/ml PDL1-blocking antibody (clone 10F.9G2, 
Biolegend) or control rat IgG (Sigma). For analysis of T-cell 
activation, OT-1 cells were harvested and stained with rat anti-
CD8-FITC (1:200, clone 53.6-7, BD), rat anti-PDL1-PE (1:200, 
clone MIH5, eBioscience), and rat anti-CD25-PerCP (1:200, clone 
PC61, Biolegend). Intracellular staining for IFN-g (1:200, clone 
XMG1.2 conjugated to APC, Biolegend) was done using the 
Cytofix/Cytoperm kit (BD) and fixable Zombi-NIR (BioLegend) 
was used for life/dead discrimination. For imLEC pre-blocking 
experiments, the PDL1-blocking antibody was incubated with the 
imLECs together with the SIINFEKL peptide pulse before washing 
and coculture with OT-1 cells. For tumor cell killing assays, OT-1 
cells were stimulated with peptide-pulsed imLECs as described 
above and subsequently cocultured with B16F10 cells expressing 
ovalbumin at a 1:5 target:effector ratio for 8 h. Zombi-NIR was 
used to determine the ratio of dead and life tumor cells. All 
activation and killing assays were performed in triplicate. Data 
were acquired on a FACS CANTO and analyzed using FlowJo.
statistical analyses
All statistical analyses were performed with GraphPad Prism 
5 (GraphPad Software Inc.). All bars indicate mean  +  SD. 
Student’s t-test was used to compare two groups, one-way 
ANOVA with Tukey’s post-test was used to compare more than 
two groups, and two-way ANOVA with Bonferroni post-test 
was used to compare data grouped by two variables. A p-value 
<0.05 was considered statistically significant (indicated by 
asterisks).
aUThOr cOnTriBUTiOns
LD designed and performed experiments, analyzed and inter-
preted the data, and wrote the manuscript. KI, TC, KK, and CH 
performed experiments, and analyzed and interpreted the data. 
MD designed experiments, interpreted data, and revised the 
manuscript.
acKnOWleDgMenTs
The authors would like to thank Catharina Seidel, Dr. Sun-Young 
Yoon, and Dr. Sarah Klein for help with tumor studies, Jeannette 
Scholl for excellent technical support, and the Scientific Center 
for Optical and Electron Microscopy (ScopeM) of the ETH 
Zurich for microscopy support.
FUnDing
This work was supported by Swiss National Science 
Foundation grants 310030B_147087 and 310030_166490, 
European Research Council grant LYVICAM, Oncosuisse, 
Krebsliga Zurich, and Leducq Foundation Transatlantic Network 
of Excellence grant Lymph Vessels in Obesity and Cardiovascular 
Disease (11CVD03) (all to MD), by the Sassella Foundation 
(15/04) and Promedica Foundation (to KI), and by an ETH 
Zurich career seed grant (SEED-71 16-1) (to LD).
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2017.00066/
full#supplementary-material.
reFerences
1. Betterman KL, Harvey NL. The lymphatic vasculature: development and 
role in shaping immunity. Immunol Rev (2016) 271(1):276–92. doi:10.1111/
imr.12413 
2. Dieterich LC, Seidel CD, Detmar M. Lymphatic vessels: new targets for 
the treatment of inflammatory diseases. Angiogenesis (2014) 17(2):359–71. 
doi:10.1007/s10456-013-9406-1 
3. Dieterich LC, Detmar M. Tumor lymphangiogenesis and new drug 
development. Adv Drug Deliv Rev (2016) 99(Pt B):148–60. doi:10.1016/j.
addr.2015.12.011 
4. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. 
Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev 
Cancer (2014) 14(3):159–72. doi:10.1038/nrc3677 
5. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. 
VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes 
tumor metastasis to distant sites. Blood (2007) 109(3):1010–7. doi:10.1182/
blood-2006-05-021758 
6. Huggenberger R, Siddiqui SS, Brander D, Ullmann S, Zimmermann K, 
Antsiferova M, et  al. An important role of lymphatic vessel activation in 
limiting acute inflammation. Blood (2011) 117(17):4667–78. doi:10.1182/
blood-2010-10-316356 
7. Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, Detmar 
M. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic 
skin inflammation. J Exp Med (2010) 207(10):2255–69. doi:10.1084/jem. 
20100559 
8. Zhou Q, Guo R, Wood R, Boyce BF, Liang Q, Wang YJ, et  al. Vascular 
endothelial growth factor C attenuates joint damage in chronic inflammatory 
13
Dieterich et al. PDL1 on Tumor-Associated Lymphatic Vessels
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 66
arthritis by accelerating local lymphatic drainage in mice. Arthritis Rheum 
(2011) 63(8):2318–28. doi:10.1002/art.30421 
9. Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger 
S, et  al. Lymphatic vessels regulate immune microenvironments in human 
and murine melanoma. J Clin Invest (2016) 126(9):3389–402. doi:10.1172/
JCI79434 
10. Kimura T, Sugaya M, Oka T, Blauvelt A, Okochi H, Sato S. Lymphatic dys-
function attenuates tumor immunity through impaired antigen presentation. 
Oncotarget (2015) 6(20):18081–93. doi:10.18632/oncotarget.4018 
11. Cohen JN, Tewalt EF, Rouhani SJ, Buonomo EL, Bruce AN, Xu X, et  al. 
Tolerogenic properties of lymphatic endothelial cells are controlled by the 
lymph node microenvironment. PLoS One (2014) 9(2):e87740. doi:10.1371/
journal.pone.0087740 
12. Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ, Qiao H, Fahl SP, et al. Lymphatic 
endothelial cells induce tolerance via PD-L1 and lack of costimulation leading 
to high-level PD-1 expression on CD8 T cells. Blood (2012) 120(24):4772–82. 
doi:10.1182/blood-2012-04-427013 
13. Cohen JN, Guidi CJ, Tewalt EF, Qiao H, Rouhani SJ, Ruddell A, et  al. 
Lymph node-resident lymphatic endothelial cells mediate peripheral tol-
erance via Aire-independent direct antigen presentation. J Exp Med (2010) 
207(4):681–8. doi:10.1084/jem.20092465 
14. Hirosue S, Vokali E, Raghavan VR, Rincon-Restrepo M, Lund AW, Corthesy-
Henrioud P, et  al. Steady-state antigen scavenging, cross-presentation, and 
CD8+ T cell priming: a new role for lymphatic endothelial cells. J Immunol 
(2014) 192(11):5002–11. doi:10.4049/jimmunol.1302492 
15. Rouhani SJ, Eccles JD, Riccardi P, Peske JD, Tewalt EF, Cohen JN, et  al. 
Roles of lymphatic endothelial cells expressing peripheral tissue antigens in 
CD4 T-cell tolerance induction. Nat Commun (2015) 6:6771. doi:10.1038/
ncomms7771 
16. Dubrot J, Duraes FV, Potin L, Capotosti F, Brighouse D, Suter T, et al. Lymph 
node stromal cells acquire peptide-MHCII complexes from dendritic cells 
and induce antigen-specific CD4(+) T cell tolerance. J Exp Med (2014) 
211(6):1153–66. doi:10.1084/jem.20132000 
17. Wherry EJ. T cell exhaustion. Nat Immunol (2011) 12(6):492–9. doi:10.1038/
ni.2035 
18. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson 
J, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule 
on microvascular endothelial cells. Microcirculation (2002) 9(2):133–45. 
doi:10.1038/sj/mn/7800123 
19. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. 
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family 
member leads to negative regulation of lymphocyte activation. J Exp Med 
(2000) 192(7):1027–34. doi:10.1084/jem.192.7.1027 
20. Vigl B, Aebischer D, Nitschke M, Iolyeva M, Rothlin T, Antsiferova O, et al. 
Tissue inflammation modulates gene expression of lymphatic endothelial 
cells and dendritic cell migration in a stimulus-dependent manner. Blood 
(2011) 118(1):205–15. doi:10.1182/blood-2010-12-326447 
21. Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas 
SN, et  al. VEGF-C promotes immune tolerance in B16 melanomas and 
cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 
(2012) 1(3):191–9. doi:10.1016/j.celrep.2012.01.005 
22. Proulx ST, Luciani P, Christiansen A, Karaman S, Blum KS, Rinderknecht 
M, et  al. Use of a PEG-conjugated bright near-infrared dye for functional 
imaging of rerouting of tumor lymphatic drainage after sentinel lymph 
node metastasis. Biomaterials (2013) 34(21):5128–37. doi:10.1016/j.
biomaterials.2013.03.034 
23. Broz ML, Krummel MF. The emerging understanding of myeloid cells 
as partners and targets in tumor rejection. Cancer Immunol Res (2015) 
3(4):313–9. doi:10.1158/2326-6066.CIR-15-0041 
24. Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, 
et  al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvi-
ronment through inhibition of NF-kappaB-induced endothelial activation. 
FASEB J (2015) 29(1):227–38. doi:10.1096/fj.14-250985 
25. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen 
VL, Dings RP, et al. Anti-angiogenesis therapy can overcome endothelial cell 
anergy and promote leukocyte-endothelium interactions and infiltration in 
tumors. FASEB J (2006) 20(6):621–30. doi:10.1096/fj.05-4493com 
26. Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, et  al. 
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ 
T-cell mediated injury in the heart. Circulation (2007) 116(18):2062–71. 
doi:10.1161/CIRCULATIONAHA.107.709360 
27. Niezgoda A, Niezgoda P, Czajkowski R. Novel approaches to treatment of 
advanced melanoma: a review on targeted therapy and immunotherapy. 
Biomed Res Int (2015) 2015:851387. doi:10.1155/2015/851387 
28. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer 
immunotherapy. Mol Cancer Ther (2015) 14(4):847–56. doi:10.1158/1535-
7163.MCT-14-0983 
29. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et  al. 
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A 
in cancer patients. Nature (2014) 515(7528):563–7. doi:10.1038/nature14011 
30. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya 
E, et  al. Nivolumab versus docetaxel in advanced squamous-cell non-
small-cell lung cancer. N Engl J Med (2015) 373(2):123–35. doi:10.1056/
NEJMoa1504627 
31. Broggi MA, Schmaler M, Lagarde N, Rossi SW. Isolation of murine lymph 
node stromal cells. J Vis Exp (2014) (90):e51803. doi:10.3791/51803 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2017 Dieterich, Ikenberg, Cetintas, Kapaklikaya, Hutmacher and 
Detmar. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
